Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients

Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients

April 02, 2019

Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing guidelines to include clear recommendations for multigene panel testing in patients with cancer. According to the study, patients with ovarian, breast, pancreatic, prostate and colorectal cancer with potentially actionable germline variants are being missed each year when clinicians adhere to guidelines ...

Read more


Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

March 14, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City.

A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly ...

Read more


Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

March 06, 2019

Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters’ option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae’s recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters’ option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other ...

Read more


Invitae Announces Pricing of Public Offering of Common Stock

Invitae Announces Pricing of Public Offering of Common Stock

March 05, 2019

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million. The offering is expected to close on or about March 8, 2019 ...

Read more


Invitae Announces Proposed Public Offering of Common Stock

Invitae Announces Proposed Public Offering of Common Stock

March 04, 2019

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The ...

Read more


Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

February 26, 2019

Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure

As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Invitae Corporation (NYSE: NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (NASDAQ: XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis ...

Read more


Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

February 19, 2019

Annual volume, revenue exceed increased guidance for full-year 2018
Guided to more than 500,000 test samples, $220 million in revenue expected in 2019
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018.

“In just five years, we have provided more than half a million people with high quality, comprehensive ...

Read more


Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 13, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City.

A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be ...

Read more


Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

February 12, 2019

In Combination with Carrier Screening, NIPS Provides Affordable, Streamlined Access to Genetic Testing for Parents-to-Be

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced the addition of non-invasive prenatal screening (NIPS) to the company’s comprehensive women’s health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for ...

Read more


New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought

New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought

February 07, 2019

Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis

Testing Guidelines Still Exclude At-Risk Patients

The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in JAMA Oncology by researchers from Tulane Cancer Center and Invitae (NYSE: NVTA), a leading genetics company. In addition ...

Read more